Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

Analyst Ratings

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $13.60 (134.48% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016Robert W. BairdInitiated CoverageNeutral$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016Brean CapitalReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016MizuhoReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2015Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Cantor FitzgeraldReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2015GuggenheimInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016Q216($0.27)$33.35 millionN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2016Q116($0.38)($0.33)$24.16 million$21.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.41)($0.41)$31.73 million$21.42 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.40)($0.38)$14.04 million$16.44 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.31)($0.21)$17.57 million$36.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.30)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q4($0.23)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.12)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.32)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114($0.30)($0.27)$11.93 million$13.03 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014($0.29)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013($0.34)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.28)($0.31)$13.68 million$18.45 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2013Q4 2012($0.26)($1.76)$11.77 million$12.58 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2012Q312($1.81)$8.60 million$11.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Merrimack Pharmaceuticals (NASDAQ:MACK)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Merrimack Pharmaceuticals (NASDAQ:MACK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/25/2016Birgit M SchoeberlInsiderSell50,000$5.50$275,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateHeadline
07/30/16 07:55 AMNajarian Stake Brings Out Merrimack Pharmaceuticals Inc (MACK) Option Bulls
07/29/16 05:12 PMCan Shares Of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Hit $16? - Investor Newswire
07/29/16 11:47 AMETF’s with exposure to Merrimack Pharmaceuticals, Inc. : July 29, 2016 -
07/29/16 08:04 AMAnalysts Spotlight: Baxter International Inc. (NYSE:BAX) , Merrimack ... - Street Updates
07/28/16 08:12 AMNew Broker Ratings For Merrimack Pharmaceuticals, Inc. (MACK ... - FTSE News
07/28/16 08:12 AMLatest Analysts Tips Update: Baxter International Inc. (NYSE:BAX) , Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Street Updates
07/28/16 08:12 AMCurrent Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) PT ... - Review Fortune
07/26/16 05:21 PMStocks Worth Mentioning Ratings-Wise: Tiffany & Co. (NYSE:TIF), Merrimack Pharmaceuticals Inc (NASDAQ:MACK) - Review Fortune
07/26/16 05:21 PMStock Update (NASDAQ:MACK): Merrimack Pharmaceuticals Inc Announces ONIVYDE® Regimen Receives Positive ... - Smarter Analyst
07/26/16 08:09 AMMerrimack Pharmaceuticals (MACK) Up on EU Nod
07/26/16 08:09 AMMerrimack's (MACK) ONIVYDE Receives Positive CHMP Opinion
07/25/16 05:12 PMIntraday Active Biotech Stocks News: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Merrimack Pharmaceuticals ... - The Voice Registrar
07/25/16 09:35 AMStocks Logging Active Run: Wal-Mart Stores (NYSE:WMT), Merrimack Pharmaceuticals (NASDAQ:MACK), G-III Apparel ... - Seneca Globe
07/25/16 09:35 AMStocks inside Analysts Spotlight: Cigna Corporation (NYSE:CI) , Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Street Updates
07/25/16 09:35 AMHC Stocks Summary: Centene Corp (NYSE:CNC) Merrimack Pharmaceuticals Inc (NASDAQ:MACK) - share market updates (press release)
07/25/16 01:28 AMMerrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union - [at noodls] - CAMBRIDGE, Mass., July 25, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
07/23/16 04:43 PMWhich way Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insiders are heading - Review Fortune
07/21/16 05:17 PMMomentum Stocks in Focus: Xilinx Inc. (XLNX) Merrimack Pharmaceuticals, Inc. (MACK) HCA Holdings, Inc. (HCA) - iStreetWire
07/21/16 05:17 PMMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 05:17 PMPrice Target Highlight: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - News Oracle
07/21/16 05:17 PMMerrimack Pharmaceuticals Inc. (MACK) Jumps 6.19% on July 20 - Equities.com
07/21/16 07:53 AMVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Rises, Analysts: Hold Rating
07/20/16 08:00 AMStock Moving Lower for the Month; Investor Update on Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Engelwood Daily
07/19/16 03:05 PMMerrimack Announces Timing of Second Quarter 2016 Investor Conference Call - [PR Newswire] - The call will cover an update on Merrimack's progress as well as a summary of second quarter 2016 financials. A listen-only webcast of the call will be available in the Investors section of Merrimack's website, investors.merrimack.com, and a replay of the call will be archived there for six weeks. Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge.
07/18/16 10:23 AMStock to Track: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - News Oracle
07/17/16 09:23 AMShares Moving Down on the Week: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Engelwood Daily
07/17/16 09:23 AMHow Analysts Feel About Merrimack Pharmaceuticals Inc (NASDAQ:MACK)? - Press Telegraph
07/16/16 08:25 AMMerrimack Pharmaceuticals (MACK): Price Target and June Short Interest Disclosure - Trade Calls
07/16/16 08:25 AMMerrimack Pharmaceuticals Inc. (MACK) Jumps 5.08% on July 15 - Equities.com
07/15/16 04:06 PMMerrimack Pharmaceuticals : FDA Grants Merrimack Fast Track Designation for Seribantumab MM-121 in Non-small Cell Lung Cancer
07/15/16 09:23 AMAnalysts Review of Stocks: Amicus Therapeutics, Inc. (NASDAQ:FOLD) , Merrimack Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
07/14/16 05:19 PMIntraday Active Biotech Stocks News: Relypsa, Inc. (NASDAQ:RLYP), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - The Voice Registrar
07/14/16 05:19 PMMerrimack Pharmaceuticals Inc Realized Volatility Hits Elevated Level - CML News
07/14/16 05:19 PMMerrimack Pharmaceuticals Inc. (MACK) Drops 5.8% on July 13 - Equities.com
07/14/16 08:41 AMBiotechnology Equities Technical Updates -- Merrimack Pharma, Alnylam Pharma, CytRx, and Progenics Pharma
07/13/16 11:54 AMMerrimack Pharmaceuticals Stock Sank Like a Stone in June - The Brexit vote claimed another victim.
07/12/16 05:19 PMAnalyst Target and Average Rating Watch: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Press Telegraph
07/12/16 05:19 PMTrending Analyst Recommended Stock: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - News Oracle
07/12/16 05:19 PMOption Market: Merrimack Pharmaceuticals Inc Risk Hits An Elevated Level - CML News
07/12/16 09:27 AMCompany Shares of Merrimack Pharmaceuticals (NASDAQ:MACK) Rally 1.26% - TheFounders Daily
07/12/16 09:27 AMCurrent Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) PT Means Stock Is Worth Almost $16 - Review Fortune
07/08/16 05:09 PMDoes Merrimack Pharmaceuticals Inc Have Any Gas After Today's Huge Increase? - Press Telegraph
07/08/16 05:09 PMHealthcare Stocks in Mouthwatering Movement- Vertex Pharmaceuticals (VRTX), Merrimack Pharmaceuticals (MACK ... - Seneca Globe
07/08/16 05:09 PMIs $16 Within Reach For Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)? - Investor Newswire
07/08/16 07:57 AMMerrimack's seribantumab receives US FDA Fast Track status to treat NSCLC
07/07/16 05:07 PMMerrimack Stock Up on Fast Track Status for Seribantumab
07/06/16 05:16 PMPre-Open Stock Movers 07/06: (NTK) (EGLE) (ADXS) Higher; (GBIM) (BGI) (AAL) Lower (more...)
07/06/16 09:44 AMGlioblastoma Multiforme Treatment Market – The pipeline of GBM is currently rich in number of various therapeutic drugs
07/06/16 07:11 AMFDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer - [at noodls] - CAMBRIDGE, Mass., July 6, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted seribantumab, also known as MM-121, ...
07/05/16 04:54 PMHC Stocks Momentum: Medivation Inc (NASDAQ:MDVN), Merrimack Pharmaceuticals Inc (NASDAQ:MACK) - share market updates (press release)

Social

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MACK
  • CUSIP: 59032810
Key Metrics:
  • Previous Close: $5.61
  • 50 Day Moving Average: $5.72
  • 200 Day Moving Average: $6.59
  • P/E Ratio: N/A
  • P/E Growth: -1.28
  • Market Cap: $740.81M
  • Beta: 1.98
  • Current Year EPS Consensus Estimate: $-0.78 EPS
  • Next Year EPS Consensus Estimate: $-0.43 EPS
Additional Links:
Merrimack Pharmaceuticals (NASDAQ:MACK) Chart for Saturday, July, 30, 2016